Next Article in Journal
Isolation of Araguspongine M, a New Stereoisomer of an Araguspongine/Xestospongin alkaloid, and Dopamine from the Marine Sponge Neopetrosia exigua Collected in Palau
Previous Article in Journal
Healing and Preventive Effects of Calcium Alginate on Carbon Tetrachloride Induced Liver Injury in Rats
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antimicrobial Activity of Untenospongin B, a Metabolite from the Marine Sponge Hippospongia communis collected from the Atlantic Coast of Morocco

by
Saida Rifai
1,
Aziz Fassouane Fassouane
1,
Anake Kijjoa
2,* and
Rob Van Soest
3
1
Faculté des Sciences, University Chouaib Doukkali, Eljadida, Morocco
2
ICBAS-Instituto de Ciências Biomédicas de Abel Salazar and CIIMAR, Universidade do Porto, 4099-003 Porto, Portugal
3
Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam, P.O. Box 94766, 1090-GT, Netherlands
*
Author to whom correspondence should be addressed.
Mar. Drugs 2004, 2(3), 147-153; https://doi.org/10.3390/md203147
Submission received: 12 July 2004 / Accepted: 28 July 2004 / Published: 25 August 2004

Abstract

:
(−)-Untenospongin B isolated from the marine sponge Hippospongia communis has been tested for its antimicrobial activity against bacteria and human pathogenic fungi using agar disk method and was found to possess a broad and strong activity toward the test organisms. Its antifungal activity was further characterized by determination of the minimum inhibitory concentration (MIC) against five fungal species using broth microdilution method.

Introduction

Incidence of fungal infection is emerging worldwide and despite treatment, mortality remains high [1]. Many studies have shown an increasing frequency of systemic infections within the last decades in advanced Human Immunodeficiency Virus infected patients and other patients with deficient immune systems [2].
Currently, very few antifungal agents are available and their use may be limited by dangerous side effects [3, 4]. Furthermore, with the emergence of new triazol-resistant strains of fungi, new compounds must still be screened in search of fungicidal effect with a broad spectrum of activity and without side effects.
In the marine environment, sponges (Porifera) are one of the richest sources of both biologically active secondary metabolites and chemical diversity [5, 6]. These natural products may play a role in warding off predators, and perhaps they also repel fouling organisms. Marine sponges are also a well known source of a unique class of metabolites collectively known as C21 bisfuranoterpenes [7, 8, 9]. Early examples included (+)-furospongin-1 from Mediterranean Spongia officinalis as well as (−)-untenospongin A and B from an Okinawan Hippospongia sp. It is worth noting that (−)-untenospongin B is very closely related to another sponge metabolite (+)-tetrahydrofurospongin-1 whose stereochemistry has been well established.
During our continuing studies on bioactive substances from the Moroccan marine organisms, (−)-untenospongin B (1) was isolated from the antifungal extract of the marine sponge Hippospongia communis.
Although several biological activities were reported for bisfuranoterpenes there are no studies concerning the antifungal activity of (−)-untenospongin B against human pathogenic fungi. So the aim of this study was to investigate the antimicrobial activity of (−)-untenospongin B against human pathogenic fungi and bacteria.
Marinedrugs 02 00147f1

Results and discussion

The antimicrobial activity of (−)-untenospongin B, isolated from the Moroccan collection of the marine sponge Hippospongia communis, was evaluated against three bacteria, three yeasts and five filamentous fungi at concentration of 100 μg/disk. The results of its antibacterial and antifungal activity are summarized in Table 1. (−)-Untenospongin B has shown a broad antimicrobial activity exhibiting antibacterial activity against Escherichia coli, Bacillus subtilis as well as against the ichthyopathogenic strain Vibrio anguillarum. (−)-Untenospongin B showed also an in vitro antifungal activity against Candida albicans, Aspergillus fumigatus, and some other fungi. Light microscopy observations of the zone of fungal growth treated with (−)-untenospongin B showed the presence of non germinated cells and hyphae presenting morphological alterations, such as protoplast ejection and condensation of cytoplasm with empty spaces.
Values corresponding to MIC90 (The lowest concentration causing at least 90% of growth inhibition when compared to drug-free control) of (−)-untenospongin B and amphotericin B are given in Table 2. The results showed that the test medium had a significant influence on the MIC values. The best antifungal activity of (−)-untenospongin B for all species of fungi tested was obtained on YMA medium. Indeed, several studies have previously shown that the composition and the pH of the test medium as well as other factors such as inoculum size, time, and temperature, constitute the major variables for antifungal susceptibility [10, 11].
Comparing the antifungal activity of (−)-untenospongin B with amphotericin B, it was found that (−)-untenospongin B was more active than amphotericin B in inhibiting the growth of C. tropicalis (R2 CIP 1275.81) and F. oxysporum (CIP 108.74). On the other hand, (−)-untenospongin B showed the same activity as amphotericin B in inhibiting the growth of C. albicans (ATCC 10231) and A. niger (CIP 1082.74).
The results of our study were comparable with those of previous publications dealing with the in vitro activity of antifungal agents other than amphotericin B and from chemical compounds currently used in the hospital. For example, the in vitro susceptibility of Fusarium spp. to the new triazoles (MIC50 > 8 μg/mL) determined by Pfaller et al. [10] was less than the in vitro susceptibility of F. oxysporum (CIP 625.72) to (−)-untenospongin B.

Conclusion

The results obtained from this study suggest that marine natural products isolated from the sponges continue to be an interesting source of antifungal metabolites with better activity and that a strong in vitro antifungal activity of (−)-untenospongin B could be valuable for a development of a new drug for the treatment of fungal infections. Further studies are still needed to determine the toxicity of (−)-untenospongin B and its in vivo activity in the animal model as well as to elucidate the mechanism underlying its activity.

Experimental

General

1H and 13C NMR spectra were recorded at ambient temperature on a Bruker AMC instrument operating at 300.13 and 75.47 MHz, respectively. Rotation was determined on a Polax-2 L instrument. EI mass spectra were measured on a Hitachi Perkin – Elmer RMV-6M instrument. Silica gel for column chromatography was Si Gel 60 (0.2–0.5 nm Merck), for analytical and preparative TLC Si Gel G-60 254 Merck.

Biological material

The marine sponge Hippospongia communis was collected in March 2003 at the littoral Atlantic of El-Jadida city, Morocco. The sponge was identified by Dr. Rob van Soest, Institute for Biodiversity and Ecosystem Dynamics, University of Amsterdam. A voucher of the specimen (ZMAPOR17786) was deposited in the collections of the Zoological Museum Amsterdam. The collected material was immediately frozen at – 20°C for one night prior to extraction.

Extraction and isolation of (−)-untenospongin B

The sample (500 g wet weight) was thawed, homogenized with acetone (500 mL), allowed to stand in a dark chamber or 24 hours and filtered. The residue on the filter paper was again extracted with acetone (3×500 mL). The aqueous acetone extracts were combined, evaporated at reduced pressure until the final volume of the aqueous solution was ca. 100 mL and then extracted with CHCl3 (3 × 100 mL). The CHCl3 extracts were combined and concentrated at reduced pressure to give a viscous crude CHCl3 extract which was applied to a silica gel 60 column (64 g) and eluted with petrol-CHCl3 and CHCl3-acetone, 250 mL frs being collected as follows: frs 1–26 ( petrol-CHCl3, 1:1), 27–80 (petrol-CHCl3, 3:7), 81–97 (petrol-CHCl3, 1:9), 98–130 (CHCl3-acetone,9:1). The ratios refer to v/v.
Frs 2 and 3 (2.5 g) were combined, applied over Silica gel 60 (15g) and eluted with CHCl3-petrol, 250 mL subfrs being collected as follows: subfrs 1–20 (petrol-CHCl3, 9:1) and subfrs 21–45 (petrol-CHCl3, 4:1). Purification of subfrs 4–12 by TLC (Si gel, CHCl3-petrol, 1:1) gave 62 mg of (−)-untenospongin B which was identified by HRMS, 1H and 13C NMR measurements (1H, 13C, DEPTs, COSY, HSQC, HMBC and NOESY) as well as comparison of its proton and carbon chemical shift values and specific rotation with those reported in the literature [12].
(−)-Untenospongin B: Gum; EI-MS, m/z 326 (M+.), [α]D23 −30.9º (CHCl3, c = 0.13g/100ml).1HNMR (300 MHz, CDCl3) δ 7.36 s (H-4), 7.34 brs (H-1, H-21), 7.21 brs (H-19), 6.50 brs (H-2), 6.27 brs (H-20), 6.25 d (J =15.0, H-5), 5.89 ddd (J=15.0, 7.1, 7.1, H-6), 5.21–5.29 m (H-10, H-15), 4.44 ddd (J=7.4, 7.4, 7.4, H-11), 2.82 d (J=8.2, H-7), 2.39–2.50 m (H-17), 2.21–2.32 m (H-16), 1.69s (Me-9), 1.64 s (Me-4). 13CNMR (75.47 MHz, CDCl3) δ 143.30 (C-1), 142.72 (C-21), 139.60 (C-4), 138.82 (C-19), 136.91 (c-8), 132.18 (C-13), 128.07 (C-10), 128.06 (C-15), 127.54 (C-6), 124.58 (C-18), 124.20 (C-3), 121.09 (C-5), 110.86 (C-20), 107.48 (C-2), 65.71 (C-11), 48.04 (C-12), 42.83 (C-7), 28.40 (C-16), 24.73 (C-17), 16.68 (C-9), 16.17 (C-14).

Biological activity

Three bacteria and eight fungal species obtained from the collection of microorganisms of the Pasteur Institute (CIP) and from the American Type Culture Collection (ATCC) were used as the antimicrobial test strains: Bacillus subtilis (ATCC 66331), Escherichia coli (CIP 54127), Vibrio anguillarum (ATCC 19264), Candida albicans (ATCC 10231), Candida tropicalis (R2 CIP 1275.81, an amphotericin B and nystatin resistant strain), Cryptococcus neoformans (ATCC 11576), Aspergillus fumigatus (CIP 1082.74), Aspergillus niger (ATCC 16404), Fusarium oxysporum (CIP 625.72), Trichophyton rubrum (CIP 2043.92) and Arthroderma simii (CIP 902). The bacterial strains were maintained on the LB agar medium, the yeasts on the Sabouraud’s agar medium and the filamentous fungi were maintained on malt agar medium at 28°C. The agar disk diffusion method according to Lemriss et al. [13] was used to test antimicrobial activity of (−)-untenospongin B using casitone agar medium.
The bacteria and yeast inoculum was prepared by suspending in 9 mL of sterile water for colonies from 24 hours culture on LB and Sabouraud’s agar medium respectively. For the filamentous fungi, the inoculum was prepared with the spores derived from 5 to 15 days culture on malt agar medium. The mycelia were covered with 10 mL of distilled water and the conidia were scraped using sterile pipette. The spores were recovered after filtration on sterile absorbent cotton and were resuspended in sterile distilled water.
The cell density of each inoculum was adjusted with hemocytometer in order to obtain a final concentration of approximately 104 UFC/mL, 105 UFC/mL and 106 UFC/mL for the yeast, the filamentous fungi and for the bacteria, respectively.
Amphotericin B (Sigma) was used as positive control for yeast and fungi. Each disk contained 100 μg of (−)-untenospongin B or amphotericin B was applied on casitone agar media which were previously inoculated with each test strain. Plates were first kept at 4°C for at least 2 hours to allow the diffusion of chemicals, and then incubated at 28°C. Inhibition zones were measured after 24 hours of incubation for bacteria and C. albicans and after 48 hours of incubation for the other fungi.
The microdilution was used to evaluate the minimum inhibitory concentration (MIC) of (−)- untenospongin B. The YMA liquid medium and casitone liquid medium were used as test media. Tests were performed in 96-well round bottom sterile culture plates. The suspensions of yeast and filamentous fungi were adjusted in sterile water to match the density of a 0.5 McFarland Standard. The wells of a microdilution plate were inoculated with 180 mL of the culture medium containing a final inoculum of 0.5–2.5 103 CFU/mL. (−)-Untenospongin B and amphotericin B previously solubilized in DMSO were serially diluted two folds in the liquid medium to give a range of concentration from 640 to 0.1 μg/mL. Twenty μl of each concentration were added to wells containing culture suspension except the growth control well. The final concentration ranged from 64 to 0.01 μg/mL. Plates were incubated at 35°C for 48 hours. Fungal growth was assessed at 494 nm by measuring the optical density in each well using an enzyme immunoassay multiwell reader (Sigma diagnostic).
Table 1. In vitro antibacterial and antifungal activity of (−)-untenospongin B
Table 1. In vitro antibacterial and antifungal activity of (−)-untenospongin B
Test organismGrowth inhibition diameter (mm)

(−)-untenospongin BAmphotericin B
Bacteria
Escherichia coli13ND
Bacillus subtilis15ND
Vibrio anguillarum9ND
Yeast
Candida albicans1717
Candida tropicalis50
Cryptoccocus neoformans015
Filamentous fungi
Aspergillus fumigatus1720
Aspergillus niger1413
Arthoderma simii20ND
Trichophyton rubrum13ND
ND: not determined
Table 2. Minimum Inhibitory Concentration (MIC90) of (−)-untenospongin B and amphotericin B tested against five fungi.
Table 2. Minimum Inhibitory Concentration (MIC90) of (−)-untenospongin B and amphotericin B tested against five fungi.
Test strainMIC90 of untenospongin B (μg/ml)MIC90 of Amphotericin B (μg/ml)

CasitoneYMACasitoneYMA
C. albicans2–40.25–0.50.06–0.120.5–1
C. tropicalis4–82–416–328–16
A. fumigatus8–164–88–162–4
A. niger8–162–48–162–4
F. oxysporum1–2N.D2–48–16

Acknowledgements

This work was partially supported by the Gabinete de Relações Internacionais da Ciência e do Ensino Superior (GRICES-Portugal) and the Centre National de Recherche Scientifique et Technique (CNRST-Morocco). We thank Prof. Artur Silva of the University of Aveiro for providing the NMR spectra and Mrs. Júlia Bessa of ICBAS for technical assistance.
  • Sample Availability: Samples are available from the authors.

References

  1. Dannaoui, E.; Lortholary, O.; Dromer, F. Technique des associations d’antifongiques in vitro et in vivo chez l’animal. J. Mycol. Med 2003, 13, 73–85. [Google Scholar]
  2. Thiebaut, A. Empirical treatment by antifungal drugs in febrile neutropenia. J. Mycol. Med 2002, 12, 115–119. [Google Scholar]
  3. Lorthoraly, O.; Denning, W. D.; Dupont, B. Endemic mycoses: a treatment update. J. Antimicrob. Chemother 1999, 43, 321–331. [Google Scholar]
  4. Andriole, V.T. Current and future antifungal therapy: new targets for antifungal agents. J. Antimicrob. Chemother 1999, 44, 151–162. [Google Scholar]
  5. Kijjoa, A.; Sawangwong, P. Drugs and cosmetics from the Sea. Mar. Drugs 2004, 2, 73–82. [Google Scholar]
  6. Proksch, P.; Ebel, R.E.; Ebel, R. Drugs from the sea-opportunities and obstacles. Mar. Drugs 2003, 1, 5–17. [Google Scholar]
  7. Fontana, A.; Albarella, L.; Scognamiglio, G.; Uriz, M.; Cimino, G. Structural and stereochemical studies of C-21 terpenoids from Mediterranean Spongiidae sponges. J. Nat. Prod 1996, 59, 869–872. [Google Scholar]
  8. Rochfort, S. J.; Atkin, D.; Hobbs, L.; Capon, R.J. Hippospongins A-C : new furanoterpenes from Australian marine sponge Hippospongia sp. J. Nat. Prod 1996, 59, 1024–1028. [Google Scholar]
  9. Capon, R. J.; Jekins, A.; Rooney, F.; Ghisalberti, E. L. Structure revision and assignment of absolute stereochemistry of a marine C21 bisfuranoterpene. J. Nat. Prod 2001, 64, 638–639. [Google Scholar]
  10. Ryder, N.S.; Wagner, S.; Leitner, I. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and others pathogenic yeasts. Antimicrob. Agents Chemother 1998, 42, 1057–1061. [Google Scholar]
  11. Pfaller, M.A.; Messer, S.A.; Boyken, L.; Huynh, H.; Hollis, R.J.; Diekema, D.J. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using national committee for clinical laboratory standards susceptibility testing methods. Antimicrob. Agents Chemother 2002, 46, 3518–3521. [Google Scholar]
  12. Umeyama, A.; Shoji, N.; Arihara, S.; Ohizumi, Y.; Kobayashi, J. Untenospongin A and B, Novel furanoterpenes with coronary vasodilating activity from the Okinawan marine sponge Hippospongia sp. Aust. J. Chem 1989, 42, 459–462. [Google Scholar]
  13. Lemriss, S.; Marquet, B.; Ginestet, H.; Lefeuvre, L.; Fassouane, A.; Boiron, P. Screening of new antifungal compounds in a collection of chemical products. J. Mycol. Med 2003, 13, 189–192. [Google Scholar]

Share and Cite

MDPI and ACS Style

Rifai, S.; Fassouane, A.F.; Kijjoa, A.; Van Soest, R. Antimicrobial Activity of Untenospongin B, a Metabolite from the Marine Sponge Hippospongia communis collected from the Atlantic Coast of Morocco. Mar. Drugs 2004, 2, 147-153. https://doi.org/10.3390/md203147

AMA Style

Rifai S, Fassouane AF, Kijjoa A, Van Soest R. Antimicrobial Activity of Untenospongin B, a Metabolite from the Marine Sponge Hippospongia communis collected from the Atlantic Coast of Morocco. Marine Drugs. 2004; 2(3):147-153. https://doi.org/10.3390/md203147

Chicago/Turabian Style

Rifai, Saida, Aziz Fassouane Fassouane, Anake Kijjoa, and Rob Van Soest. 2004. "Antimicrobial Activity of Untenospongin B, a Metabolite from the Marine Sponge Hippospongia communis collected from the Atlantic Coast of Morocco" Marine Drugs 2, no. 3: 147-153. https://doi.org/10.3390/md203147

Article Metrics

Back to TopTop